The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality

2016 ◽  
Vol 26 (4) ◽  
pp. 446-458
Author(s):  
Catherine B. Johannes ◽  
Lisa J. McQuay ◽  
Kirk D. Midkiff ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
2016 ◽  
Vol 36 (12) ◽  
pp. 993-999 ◽  
Author(s):  
Carlos A. Camargo ◽  
Kourtney J. Davis ◽  
Elizabeth B. Andrews ◽  
David A. Stempel ◽  
Michael Schatz

2008 ◽  
Vol 121 (2) ◽  
pp. S142-S142
Author(s):  
P GOMEZDINGER ◽  
M KAPLAN ◽  
B GOLDBERG ◽  
A STAVEREN ◽  
J HSU

2021 ◽  
pp. 1942602X2110369
Author(s):  
Anil Nanda ◽  
Anne F. Russell ◽  
Theresa A. Bingemann

Asthma is the most common noncommunicable chronic childhood disease, affecting more than 5 million children in the United States. Asthma is the leading cause of school absenteeism. Treatments for asthma are divided into fast-acting medications that are used to relieve symptoms and slower acting (controller) medications that prevent symptoms. Albuterol is the most common fast acting medication for asthma, and it exists in multiple forms, including metered-dose inhaler and nebulized therapy. The use of spacers and holding chambers can further improve medication deposition in the airway. The cornerstone controller therapy for asthma is inhaled corticosteroid. Other medications for asthma include long-acting beta agonists, long-acting antimuscarinics, and antileukotrienes. The newest agents for controller asthma therapies are biologics.


Sign in / Sign up

Export Citation Format

Share Document